PEPG

PepGen Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website epgen.com
Employees(FY) 63
ISIN US7133171055

Performance

-1.35%

1W

+4.53%

1M

-5.26%

3M

+216.35%

6M

+93.53%

YTD

-9.37%

1Y

Profile

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that id in Phase I clinical trial to treat individuals with Duchenne muscular dystrophy (DMD). The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is headquartered in Boston, Massachusetts.

Advanced Technical Analysis

Technical Analysis of PEPG 2024-05-10

Overview:

In analyzing the technical indicators for PEPG over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement. By examining these key factors, we aim to offer valuable insights and predictions for the upcoming days.

Trend Analysis:

...

See more ...

Recent News & Updates

2024-05-15 01:20
PepGen Q1 Loss Narrows(Yahoo Finance)
2024-05-14 10:55
PEPG Stock Earnings: PepGen Beats EPS for Q1 2024(Investorplace)
2024-05-14 04:02
PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights(Globenewswire)
2024-04-25 10:00
Best Momentum Stocks to Buy for April 25th(Zacks)
2024-04-12 01:30
Hedge Fund and Insider Trading News: ExodusPoint Capital Management, Bridgewater Associates, Glenview Capital Management, PepGen Inc. (PEPG), HCI Group Inc (HCI), and More(Insidermonkey)
2024-03-13 16:05
PepGen to Participate in Upcoming Investor Conferences(GlobeNewswire)
2024-03-13 07:00
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy(GlobeNewswire)
2024-03-13 04:05
PepGen to Participate in Upcoming Investor Conferences(Globenewswire)
2024-03-12 19:00
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy(Globenewswire)
2024-03-12 09:55
Can PepGen, Inc. (PEPG) Climb 48.62% to Reach the Level Wall Street Analysts Expect?(Zacks)
2024-03-11 21:55
Can PepGen, Inc. (PEPG) Climb 48.62% to Reach the Level Wall Street Analysts Expect?(Zacks)
2024-03-11 12:00
PepGen, Inc. (PEPG) Upgraded to Buy: What Does It Mean for the Stock?(Zacks)
2024-03-11 00:00
PepGen, Inc. (PEPG) Upgraded to Buy: What Does It Mean for the Stock?(Zacks)
2024-03-06 16:01
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments(GlobeNewswire)
2024-03-06 10:54
PEPG Stock Earnings: PepGen Beats EPS for Q4 2023(Investorplace)
2024-03-06 03:01
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments(Globenewswire)
2024-03-04 07:00
PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy(GlobeNewswire)
2024-03-03 18:00
PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy(Globenewswire)
2024-02-28 14:02
14 Stocks With Heavy Insider Buying In 2024(Insidermonkey)
2024-02-20 08:00
PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1(GlobeNewswire)
2024-02-19 19:00
PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1(Globenewswire)
2024-02-07 07:30
PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock(GlobeNewswire)
2024-02-06 18:30
PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock(Globenewswire)
2024-01-17 07:00
Mary Beth DeLena Joins PepGen as General Counsel and Secretary(GlobeNewswire)
2024-01-16 18:00
Mary Beth DeLena Joins PepGen as General Counsel and Secretary(Globenewswire)
2024-01-12 05:11
Institutions own 24% of PepGen Inc. (NASDAQ:PEPG) shares but private equity firms control 54% of the company(Simply Wall St.)
2024-01-08 07:00
PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping(GlobeNewswire)
2024-01-07 18:00
PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping(Globenewswire)
2023-12-18 08:00
PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)(GlobeNewswire)
2023-12-17 19:00
PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)(Globenewswire)

Page 1 of 3

previousnext